Slingshot Insights

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

BLCM

100%

Additional Information

Management Comment "Our GoCAR-T product candidate BPX-601 contains our proprietary iMC or inducible MyD88/CD40 activation switch that is designed to treat solid tumors expressing prostate stem cell antigen or PSCA. Unlike standard CARs, which is depended on antigen for activation and proliferation, GoCAR-T places the co-stimulatory signal on the rimiducid controlled switch which designed to allow control the T cell survival in the absence of antigen signaling and full activation and proliferation in the presence of both antigen and rimiducid.We will be studying BPX-601 in solid tumors over expressing PSCA, an attractive proprietary target in which there is significant unmet medical need. The initial planned indication is non-resectable pancreatic cancer and the initial Phase I clinical trial is also expected to begin enrollment in mid 2016. Preclinical data with BPX-601 presented at ASH 2015 showed strong antitumor activity and enhanced T cell proliferation, persistence and in vivo anti-tumor activity compared to traditional CAR T therapies."-CEO Tom Farrell

http://seekingalpha....

Additional Relevant Details See the Q&A with Biren Amin at the end of this source for additional information

http://seekingalpha....

Catalyst

Do you think this event is important to the companies below? How will it affect their stock price?

Additional Information

Slingshot Insights Explained